Investigational drug · Phase 3
Sefaxersen
Also called: RO7434656
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary IgA Nephropathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Sefaxersen"
First trial start
2023
Aug 8, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sefaxersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary IgA Nephropathy
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Sefaxersen" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05797610 · 459 participants · Start Aug 8, 2023 · Primary completion May 25, 2028
Drug: Sefaxersen (RO7434656); Placebo · For: Primary IgA Nephropathy
Sites: Birmingham, Alabama; Glendale, California; Los Angeles, California · 162 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- GOLDEN: Efficacy and Safety of Complement Factor B Antisense, Sefaxersen, in Geographic Atrophy due to Age-Related Macular Degeneration.
Jaffe GJ, Wykoff CC, McCaleb ML, et al. · Ophthalmol Sci 2026
- A First-in-Japanese Phase 1, Double-Blind, Placebo-Controlled, Parallel-Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants.
Sato T, Fukase H, Ishida T, et al. · Clin Pharmacol Drug Dev 2026
- The expanding role of complement inhibitors in the treatment of IgA nephropathy.
Caravaca-Fontán F, Praga M · Kidney Int 2026
- A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy.
Barbour SJ, Hladunewich MA, McCaleb ML, et al. · Kidney Int 2026
- Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen.
McCaleb ML, Hughes SG, Grossman TR, et al. · Immunobiology 2025
Also in development for Primary IgA Nephropathy
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- SHR-2173Phase 25 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.